Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andreas Kamlot

Surgery Danville, CA Medical Doctor

NPI 1720019748 CMS profile 350670

1320 El Capitan Dr, Ste 120, Danville, CA 94526

Open in the dashboard

General payments

$540,017

975 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andreas Kamlot of Danville, CA is reported in the CMS Open Payments database as having received $540,017 across 975 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,667 62
2024 General $61,669 115
2023 General $40,565 91
2022 General $123,022 205
2021 General $112,858 190
2020 General $77,158 108
2019 General $112,079 204

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andreas Kamlot
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Andreas Kamlot were reported at $12,667. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Andreas Kamlot Surgery median Middle half National median
2019 $112,079 $253 $82–$1,521 $163
2020 $77,158 $131 $40–$706 $114
2021 $112,858 $168 $50–$904 $132
2022 $123,022 $224 $76–$1,218 $149
2023 $40,565 $253 $82–$1,255 $160
2024 $61,669 $279 $90–$1,381 $164
2025 $12,667 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Atricure, Inc. $533,267 800 payments
  2. Edwards Lifesciences Corporation $3,347 124 payments
  3. Medtronic Vascular, Inc. $1,106 11 payments
  4. Abiomed $697 9 payments
  5. Abbott Laboratories $569 11 payments
  6. Impulse Dynamics (USA) Inc. $172 1 payment
  7. Becton, Dickinson and Company $129 1 payment
  8. Medtronic, Inc. $125 1 payment
  9. HeartFlow, Inc. $121 1 payment
  10. Shockwave Medical, Inc $66 2 payments
  11. Other $418 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $458,950 181 payments
  2. Travel and Lodging $61,983 270 payments
  3. Food and Beverage $19,085 524 payments
Products named General payments · program years 2019–2025
  1. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $338,462 486 payments
  2. EPI-SENSE GUIDED COAGULATION SYS $159,973 202 payments
  3. ATRICLIP LAA EXCLUSION SYSTEM $132,889 215 payments
  4. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, MODELS $13,107 16 payments
  5. SYNERGY ABLATION SYSTEM $5,891 31 payments
  6. AtriCure cryoICE cryoSPHERE Cryoablation System $2,951 13 payments
  7. ATRICURE SYNERGY ABLATION SYSTEM $2,516 16 payments
  8. ISOLATOR SURGICAL ABLATION SYSTEM $1,505 3 payments
  9. DISSECTOR $1,505 3 payments
  10. CoreValve Evolut $1,106 11 payments
  11. Other $5,368 167 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

81

Median for Cardiac Surgery: 68

Drug cost

$458

Median for Cardiac Surgery: $445

Branded share of claims

0%

Median for Cardiac Surgery: 15.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Amiodarone Hcl Generic 23 $261
Mupirocin Generic 14 $97
Prednisone Generic 19 $47
Metoprolol Tartrate Generic 14 $43
Furosemide Generic 11 $10

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 411 Part D prescribers listed as Cardiac Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$219,513

Medicare's payments for the services billed

Medicare patients

306

Average age 75

Services billed

782

108 women, 198 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 64%
Diabetes 53%
Heart failure 48%
Atrial fibrillation 48%
Chronic kidney disease 47%
Arthritis 42%
COPD 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

975 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record